CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA upon the dosing of the first patient in a clinical study of IMO-2055 in combination with Erbitux® and Camptosar® in patients with colorectal cancer. Under the terms of the agreement, the Company is entitled to receive a payment of €3.0 million ($3.8 million) from Merck KGaA, the global pharmaceutical and chemical company based in Darmstadt, Germany.
